annb0t
Top 20
Immutep Limited
Media Release
New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma Deep, durable responses seen across all PD-L1 subgroups with a 13.5% Complete Response rate and median Duration of Response not yet reached (minimum follow-up of 17 months) In the overall patient population, regardless of PD-L1 expression, a strong response rate of 29.7% and
12-month overall survi...
>>> Read more: Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
Media Release
New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma Deep, durable responses seen across all PD-L1 subgroups with a 13.5% Complete Response rate and median Duration of Response not yet reached (minimum follow-up of 17 months) In the overall patient population, regardless of PD-L1 expression, a strong response rate of 29.7% and
12-month overall survi...
>>> Read more: Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
